Live Breaking News & Updates on Fosun Pharma Artesun

Performance Highlights:
During the reporting period, the revenue was RMB 43.952 billion, with a year-on-year growth of 12.66%; the net profit after deducting extraordinary gain or loss attributable. | March 28, 2023 ....

United States , Macau General , Hong Kong , Fosun Pharma Artesun , Han Li Kang Rituximab , Getz Pharma , Parsabiv Etelcalcetide , Han Si Zhuang Serplulimab , Han Li Kang , Fosun Pharma , Tridem Pharma , Wu Yifang , Han Si Zhuang , National Medical Insurance Drug Catalogue , European Commission , National Reimbursement Drug List , Rating Expert Committee , Sinopharm Co Ltd , Innovation For Good Health , Performance Highlights , Han Qu You , Chinese Mainland , Shanghai Fosun Pharmaceutical , Stock Code , Reporting Period , Increased Rd Investment ,